Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Multiple Sclerosis

    San Diego, CA

    Search
    Multiple Sclerosis
    San Diego, CA
    Show Map
    Map View
    San Diego, CA

    Popular Searches

    By Condition

    Depression Clinical Trials in California

    Anxiety Clinical Trials in California

    Schizophrenia Clinical Trials in California

    ADHD Clinical Trials in California

    Bipolar Disorder Clinical Trials in California

    Multiple Sclerosis Clinical Trials in California

    Autism Clinical Trials in California

    Treatment Resistant Depression Clinical Trials in California

    Borderline Personality Disorder Clinical Trials in California

    Social Anxiety Disorder Clinical Trials in California

    Parkinson's Disease Clinical Trials in California

    Alzheimer's Disease Clinical Trials in California

    By Location

    Clinical Trials near Los Angeles, CA

    Clinical Trials near San Francisco, CA

    Clinical Trials near San Diego, CA

    Clinical Trials near Sacramento, CA

    Clinical Trials near La Jolla, CA

    Clinical Trials near Orange, CA

    Clinical Trials near Stanford, CA

    Clinical Trials near Palo Alto, CA

    Clinical Trials near Long Beach, CA

    Clinical Trials near Duarte, CA

    Clinical Trials near Oakland, CA

    Clinical Trials near Torrance, CA

    Other People Viewed

    By Subject

    26 Multiple Sclerosis Trials near Dallas, TX

    16 Multiple Sclerosis Trials near Knoxville, TN

    27 Multiple Sclerosis Trials near Philadelphia, PA

    27 Multiple Sclerosis Trials near Richmond, VA

    18 Multiple Sclerosis Trials near Houston, TX

    53 Multiple Sclerosis Trials near New York, NY

    48 Psoriasis Trials near San Diego, CA

    79 Osteoporosis Trials near San Diego, CA

    140 Clinical Trials near Centennial, CO

    Top Primary Progressive Multiple Sclerosis Clinical Trials

    Top Multiple Sclerosis Clinical Trials

    Top Amyotrophic Lateral Sclerosis Clinical Trials

    By Trial

    Ocrelizumab for Multiple Sclerosis

    Ofatumumab for Multiple Sclerosis

    Ocrelizumab for Pediatric Multiple Sclerosis

    Ozanimod vs Fingolimod for Multiple Sclerosis

    Peginterferon Beta-1a for Multiple Sclerosis

    StableEyes for Dizziness in Multiple Sclerosis

    Cognitive Behavioral Therapy for Insomnia in Multiple Sclerosis

    Diets + Behavioral Support for MS

    Immunotherapy + TACE +/- Lenvatinib for Liver Cancer

    Torso Weighting for Multiple Sclerosis

    CGuard Prime Carotid Stent for Stroke

    RIC Regimen for Nonmalignant Diseases

    Related Searches

    Top Osteoarthritis Clinical Trials near Chicago, IL

    Top Osteoarthritis Clinical Trials near San Diego, CA

    Top Parkinsons-disease Clinical Trials near Atlanta, GA

    Stellate Ganglion Block for Atrial Fibrillation

    Me-4FDG PET/CT Scan for Lung Cancer

    TMS for Parkinson's Disease Apathy

    KER-050 for Myelofibrosis

    Secukinumab for Psoriatic Arthritis

    Legal Services for Caregivers of Colorectal Cancer Patients

    Top Clinical Trials near Dilworth, MN

    177Lu-PSMA-617 for Prostate Cancer

    Enlicitide + Rosuvastatin for High Cholesterol

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      70 Multiple Sclerosis Trials near San Diego, CA

      Power is an online platform that helps thousands of Multiple Sclerosis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Remibrutinib vs Teriflunomide for Multiple Sclerosis

      Los Angeles, California
      This trial compares two medications, remibrutinib and teriflunomide, for treating patients with relapsing multiple sclerosis. These patients have repeated episodes of symptoms and need effective treatments. The medications work by controlling the immune system to prevent it from causing damage to the nervous system. Teriflunomide is an approved medication for adults with relapsing multiple sclerosis.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:PPMS, CNS Disease, Substance Abuse, Others
      Must Not Be Taking:Leflunomide, Methotrexate, CYP3A4 Inhibitors

      800 Participants Needed

      Ozanimod for Multiple Sclerosis

      Arcadia, California
      This is a multicenter, longitudinal, single-arm, open-label study to describe the change from baseline in cognitive processing speed, measured by the SDMT, in subjects with RMS treated with ozanimod HCl 1 mg at 3 years. All subjects will receive orally administered ozanimod HCl 1 mg. The primary efficacy endpoint is the proportion of subjects with a clinically meaningful increase in raw score of ≥ 4 points or 10% from baseline (improved). The treatment period is 36 months. For all subjects who finish the subject and for those who discontinue, there will be a 30-day (± 15 days) and a 90-day (± 10 days) Safety Follow-up Visit. There is no planned protocol extension following the end of the study. Approximately 250 subjects with RMS will be recruited for this study. Subjects with RMS will be enrolled in this study if they have received ≤ 1 DMT, have an EDSS ≤ 3.5, and have been diagnosed with RMS within 5 years of study entry. The Investigator will be responsible for the overall conduct of the study at the site, confirmation of subject eligibility, routine study subject clinical management including for MS relapses, and management of AEs.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Hepatic Disease, Neurologic Disorders, Others
      Must Be Taking:Ozanimod

      250 Participants Needed

      Fingolimod for Pediatric Multiple Sclerosis

      Los Angeles, California
      To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Progressive MS, Chronic Immune Disease, Others

      240 Participants Needed

      Fasting Mimicking Diet for Multiple Sclerosis

      Los Angeles, California
      In the proposed study, investigators will assess the safety and feasibility of cycles of a fasting mimicking diet (FMD) and its effect on Multiple Sclerosis Quality of Life (MSQOL) in relapsing MS (RMS) patients treated with standard disease modifying therapies (FMDMS). To test the primary hypothesis, investigators will compare the composite quality of life score in terms of improvement in disability, fatigue, and cognitive function with the fasting protocol, as compared to a Mediterranean diet (control) group alone. Further, investigators hypothesize that the effects will remain for at least 6-months after the last FMD cycle. The Mediterranean diet (MD) has been chosen as the control diet to minimize baseline dietary differences among patients. It has been trialed for feasibility in Multiple Sclerosis patients and used in a previous human FMD trial for MS patients where a FMD followed by MD was shown to have positive effects on people with MS.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Malignancy, Pregnancy, Diabetes, Others
      Must Not Be Taking:Glucocorticoids

      50 Participants Needed

      RP2/RP3 + Atezolizumab + Bevacizumab for Colorectal Cancer

      Los Angeles, California
      This is an open-label, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Hepatitis, HIV, CNS Metastases, Others
      Must Not Be Taking:Antivirals, Immunosuppressants

      4 Participants Needed

      ATP128 + VSV-GP128 + BI 754091 for Colorectal Cancer

      Los Angeles, California
      This is a multi-center, non-randomised Phase 1b study to evaluate the safety and tolerability of ATP128 alone or in combination with BI 754091 and of heterologous prime-boost ATP128 + VSV-GP128 in combination with BI 754091. ATP128 is a self-adjuvanted chimeric recombinant protein vaccine being developed in combination with programmed cell death 1 (PD-1) blockade for the treatment of microsatellite stable (MSS) patients not responding to PD-1 blockade. The PD-1 inhibitor being tested with ATP128 is the BI 754091 (Ezabenlimab) compound which belongs to the human immunoglobulin G4 (IgG4) subclass of antibodies. VSV-GP is a recombinant chimeric vesicular stomatitis virus (VSV, Indiana strain Rhabdoviridae) which carries the envelope glycoprotein (GP) of the visceral non neurotropic WE-HPI strain of the Lymphocytic choriomeningitis virus (LCMV, Arenaviridae) instead of the native VSV glycoprotein (G) and is developed as integral part of the prime-boost regimen together with ATP128. The Sponsor plans to enrol 96 patients with histologically or cytologically confirmed stage IV colorectal cancer coming form three different patient populations: * Cohort 1a: 6 patients with stage IV colorectal cancer (CRC) having failed standard of care (SoC) therapies * Cohorts 1b, 2a, 2c: 30 patients with stage IV microsatellite stable/mismatch repair-proficient (MSS/MMRp) CRC being in stable disease (SD) or partial response (PR) after first line of SoC (4-6 months duration at minimum) * Cohorts 2b, 4b: 30 patients with stage IV MSS/MMRp liver-limited disease Patients eligible for this study will be enrolled in one of the 8 cohorts depending on their disease: * Patients in Cohort 1a will receive ATP128 as single agent * Patients in Cohorts 1b, 2a, 2b, 2c will receive ATP128 in combination with BI 754091 * Patients in Cohorts 3, 4a, 4b will receive ATP128 and VSV-GP128 in combination with BI 754091
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Active Infection, CNS Metastasis, Others
      Must Not Be Taking:Checkpoint Inhibitors, Immunotherapy

      96 Participants Needed

      Ublituximab for Multiple Sclerosis

      Pasadena, California
      The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Pregnancy, Malignancy, Others
      Must Be Taking:Ublituximab

      1100 Participants Needed

      Obexelimab for Multiple Sclerosis

      West Hollywood, California
      This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Primary Progressive MS, Neuromyelitis Optica, Others

      93 Participants Needed

      Metformin for Progressive Multiple Sclerosis

      Los Angeles, California
      This trial is testing metformin, a diabetes medication, to see if it can help adults aged 30-65 with progressive multiple sclerosis. The goal is to find out if metformin can reduce inflammation and protect nerve cells, potentially slowing down the disease.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Early Phase 1
      Age:30 - 65

      Key Eligibility Criteria

      Disqualifiers:Renal Dysfunction, Hepatic Dysfunction, Others
      Must Not Be Taking:Glucocorticoids, Metformin, Others

      44 Participants Needed

      Ozanimod for Multiple Sclerosis

      Las Vegas, Nevada
      A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Progressive MS, Uncontrolled Diabetes, Cancer, Others
      Must Be Taking:Anti-CD20 Therapy

      100 Participants Needed

      Intensive vs Escalation Therapy Approaches for Multiple Sclerosis

      Las Vegas, Nevada
      The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide overall treatment philosophy and will be applicable not only to a wide range of existing therapies but also to new therapies, meeting a significant unmet need in patient decision making and aiding the decision for medication approval by third parties.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Contraindications To DMT, MRI Issues, Others
      Must Not Be Taking:Monoclonal Antibodies, Immunosuppressants

      800 Participants Needed

      PIPE-307 for Multiple Sclerosis

      Phoenix, Arizona
      This trial is testing a new drug called PIPE-307 to see if it can help people with relapsing-remitting multiple sclerosis. The drug likely works by calming the immune system to prevent nerve damage. The study will compare two different doses of PIPE-307 over several months.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 50

      Key Eligibility Criteria

      Disqualifiers:Optic Neuritis, Severe Myopia, Others
      Must Be Taking:Immunomodulatory DMT

      168 Participants Needed

      Frexalimab for Multiple Sclerosis

      Phoenix, Arizona
      This trial is testing a new drug called SAR441344 to see if it can reduce the number of new active brain lesions in patients. The study will also check how well the drug works overall, its safety, and how it behaves in the body. Patients will participate for several years, including screening, treatment, and follow-up periods.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:PPMS, HIV, Hepatitis B, Others
      Must Not Be Taking:Antithrombotics, Investigational Drugs

      129 Participants Needed

      IMU-838 for Multiple Sclerosis

      Phoenix, Arizona
      This trial is testing IMU-838, a medication for adults with relapsing multiple sclerosis. The drug aims to reduce immune system activity to prevent nerve damage and manage symptom flare-ups.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Non-active MS, NMO, Others
      Must Not Be Taking:Experimental Drugs, MS Treatments

      1050 Participants Needed

      IMU-838 for Multiple Sclerosis

      Scottsdale, Arizona
      This trial is testing a new medication called IMU-838 to help adults with relapsing multiple sclerosis. The goal is to see if it can reduce the frequency and severity of their symptoms. The study will evaluate the effectiveness and safety of IMU-838.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Non-active MS, Neuromyelitis Optica, Others
      Must Not Be Taking:Experimental Drugs, MS Treatments

      1050 Participants Needed

      Neuroimaging for Migraine

      Phoenix, Arizona
      The purpose of this research is to better understand brain white matter hyperintensities (WMH) in women with migraines
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:20 - 59
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Cancer, Organ Transplant, Pregnancy, Others

      50 Participants Needed

      BMS-986368 for Multiple Sclerosis

      Scottsdale, Arizona
      The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Substance Abuse, Other Spasticity, Others
      Must Not Be Taking:Cannabinoids

      200 Participants Needed

      AZD0120 for Multiple Sclerosis

      Tucson, Arizona
      This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Cardiac Conditions, CNS Disease, Others
      Must Be Taking:High Efficacy DMT

      18 Participants Needed

      Stem Cell Transplant vs Best Available Therapy for Multiple Sclerosis

      Palo Alto, California
      This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio. All participants will be followed for 72 months after randomization (Day 0, Visit 0).
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Primary Progressive MS, Hepatitis, HIV, Others
      Must Be Taking:Oral DMTs, Monoclonal Antibodies

      156 Participants Needed

      CAR T-Cell Therapy for Multiple Sclerosis

      Palo Alto, California
      A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B/C, Stroke, Others
      Must Be Taking:Anti-CD20 MAb

      120 Participants Needed

      Why Other Patients Applied

      "I've been taking Kesimpta for a couple years now and seem to be having more flare ups. I'm only 43. I have 5 kids and feel like I'm missing my life. Sleeping my life away. I'm ready to try ANYTHING for a chance at living life again."

      XJ
      Multiple Sclerosis PatientAge: 43

      "I've been using natural supplements and would like to find something more effective. My former PCP was hesitant to prescribe modafanil. I'm interested in learning about all options available to me—including the drugs currently under research investigation."

      GK
      Multiple Sclerosis PatientAge: 50

      "I've been battling multiple sclerosis for 28 years. I've tried three medications. I keep my dosing stable, but I'm just tired of managing. I want to take control of my situation."

      KE
      Multiple Sclerosis PatientAge: 43

      "I've tried 2 MS drugs but I am getting worse. I am having trouble walking long distances or for more than 30 minutes. I need to find a new medication. My doctor and I discussed some of the options in trials and I'm ready to dive in to learn more."

      OL
      Multiple Sclerosis PatientAge: 57

      "I have been losing mobility in the past 3 years very rapidly. I have tried physical therapy, but it didn't really show results. I'll admit that I am not very self-motivated, so I can use some structure. I use to be extremely active and now I am like a wet rag. So I am hoping that participating in a research trial will be of help to me."

      AK
      Multiple Sclerosis PatientAge: 75
      Match to a Multiple Sclerosis Trial

      CAR T-cell Therapy for Multiple Sclerosis

      Palo Alto, California
      A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B, Hepatitis C, Others
      Must Not Be Taking:Anticoagulants, Antiplatelets, Anti-CD20

      12 Participants Needed

      Nivolumab for Cancer

      Palo Alto, California
      This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Chemotherapy, Radiotherapy, Allogeneic Transplant, Others
      Must Not Be Taking:Anticancer Investigational Agents

      300 Participants Needed

      RO7121932 for Multiple Sclerosis

      Stanford, California
      This trial is testing a new drug called RO7121932 to see if it is safe and well-tolerated. The drug is being given to people with multiple sclerosis (MS) in different ways, either through a vein or under the skin. The goal is to find out if the drug can help treat MS without causing harmful side effects.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Active Infections, Cancer History, Neurological Disorders, Others
      Must Not Be Taking:MS Treatments, Anti-CD20 Therapies

      129 Participants Needed

      IDP-023 + Ocrelizumab for Multiple Sclerosis

      Stanford, California
      This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on autoreactive immune cells in patients with refractory progressive multiple sclerosis.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Relapsing MS, CNS Tumor, HIV, Others
      Must Be Taking:Ocrelizumab

      34 Participants Needed

      18F-OP-801 for ALS

      Stanford, California
      This trial tests a new brain scan substance called 18F-OP-801 on patients with ALS, AD, MS, PD, and healthy volunteers. It helps doctors see brain inflammation by highlighting active immune cells. This could improve early detection and treatment of these diseases.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Obesity, Alcoholism, Drug Abuse, Others
      Must Not Be Taking:Corticosteroids, NSAIDs

      65 Participants Needed

      Ofatumumab for Multiple Sclerosis

      San Francisco, California
      This study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS). The study will include lactating mothers who plan to breastfeed and initiate/re-initiate ofatumumab 2-24 weeks post-partum.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Alcohol Abuse, Immunodeficiency, Others
      Must Be Taking:Ofatumumab

      20 Participants Needed

      Ocrelizumab for Multiple Sclerosis

      San Francisco, California
      B cell-depleting therapies, such as ocrelizumab, are among the most effective medications currently available for the treatment of multiple sclerosis (MS). This suggests that B cells play a very important role in MS. While B cells are rapidly eliminated from the blood of patients treated with medications like ocrelizumab, little is known about how effectively B cells are eliminated from lymph nodes, which are important sites of B cell activation. This study is being conducted to determine to what extent B cells are targeted in lymph nodes following ocrelizumab treatment, which may have important consequences for long-term MS outcomes.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Cancer, Chronic Infection, Immunodeficiency, Others
      Must Be Taking:Ocrelizumab

      5 Participants Needed

      Ocrelizumab for Early Multiple Sclerosis

      San Francisco, California
      Newly diagnosed relapsing multiple sclerosis (MS) and high risk clinically isolated syndrome (CIS) patients will be treated with ocrelizumab at disease onset to see if treatment favorably alters CSF markers of chronic inflammation.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:18 - 50

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Progressive MS, Hepatitis, HIV, Others

      30 Participants Needed

      Myelin Repair Therapy for Multiple Sclerosis

      San Francisco, California
      The clinical trial is intended to assess for clinical evidence of Clemastine Fumarate as a myelin repair therapy in patients with acute inflammatory injury-causing demyelination as measured by multi-parametric MRI assessments. No reparative therapies exist for the treatment of acute demyelinating lesions. Clemastine fumarate was identified along with a series of other antimuscarinic medications as a potential remyelinating agent using the micropillar screen (BIMA) developed at the University of California, San Francisco (UCSF). Following in vivo validation, an FDA IND exemption was granted to investigate clemastine for the treatment of multiple sclerosis in the context of chronic optic neuropathy. That pilot study was recently completed and is the first randomized control trial documenting efficacy for a putative remyelinating agent for the treatment of MS. The preselected primary efficacy endpoint (visual evoked potential) was met and a strong trend to benefit was seen for the principal secondary endpoint assessing function (low contrast visual acuity). That trial number was 13-11577. This study seeks to follow up on that study and examine clemastine fumarate's protective and reparative effects in the context of acute demyelinating brain lesions as imaged by multi-parametric MRI assessments. The investigators will be assessing the effects of clemastine fumarate as a remyelinating therapy and assessing its effect on MRI metrics of lesions found in patients with a confirmed diagnosis of acute inflammatory injury-causing demyelination. In addition to using conventional multi-parametric MRI assessments, this study will also evaluate a new MRI technique called Ultrashort Echo Time (UTE) MRI to assess the effects of clemastine fumarate as a remyelinating therapy of acute lesions found in patients with a confirmed diagnosis of acute inflammatory injury-causing demyelination and compare it to the other assessments.

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1, 2
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Brain Atrophy, Cardiac Block, Cancer, Others
      Must Not Be Taking:Corticosteroids, Alemtuzumab, Mitoxantrone, Others

      44 Participants Needed

      Clemastine Fumarate for Multiple Sclerosis

      San Francisco, California
      This trial tests Clemastine Fumarate to see if it can repair myelin in patients with relapsing-remitting multiple sclerosis who have chronic brain lesions. The medication helps immature brain cells develop into myelin-producing cells, potentially fixing the damage caused by MS.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Brain Atrophy, Cardiac Block, Cancer, Others
      Must Not Be Taking:Corticosteroids, Alemtuzumab, Mitoxantrone, Others

      74 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Multiple Sclerosis clinical trials in San Diego, CA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Multiple Sclerosis clinical trials in San Diego, CA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Multiple Sclerosis trials in San Diego, CA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in San Diego, CA for Multiple Sclerosis is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in San Diego, CA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Multiple Sclerosis medical study in San Diego, CA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Multiple Sclerosis clinical trials in San Diego, CA?

      Most recently, we added AZD0120 for Multiple Sclerosis, Ocrelizumab Formulations for Multiple Sclerosis and P-CD19CD20-ALLO1 for Multiple Sclerosis to the Power online platform.

      What do the "Power Preferred" and "SuperSite" badges mean?

      We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

      Which clinics have received Power Preferred and SuperSite awards recruiting for Multiple Sclerosis trials in San Diego, CA?

      The Multiple Sclerosis clinics in San Diego, CA currently recognized as SuperSites are: Regina Berkovich, MD, PhD Site Number : 8400005 in West Hollywood, California

      Can MS go into remission?

      Yes. In relapsing-remitting MS the immune attack can quiet down for weeks, months, or even years, letting symptoms ease or disappear; neurologists try to extend these quiet spells—called remission or “no evidence of disease activity” (NEDA)—with early use of disease-modifying drugs, healthy habits, and regular MRI checks. Remission isn’t a cure because slow nerve damage can still smolder, and it is uncommon in secondary- or primary-progressive MS, so sticking with treatment and follow-up appointments remains vital even when you feel well.

      What is the most common cause of death in MS patients?

      Death certificates show that the commonest “underlying” cause of death in people with MS is the disease itself (ICD-10 G35), accounting for roughly half of all deaths; this label usually stands for advanced disability complicated by infections and breathing problems. Cardiovascular disease and cancer trail well behind (each about one-tenth to one-fifth of deaths), so focusing on preventing aspiration, treating infections quickly, staying mobile, and managing heart-health risks offers the biggest leverage for living longer with MS.

      What not to do if you have MS?

      Think of “don’ts” in three buckets: 1) anything that drives inflammation (smoking, heavy drinking, high-salt or highly processed, high-saturated-fat foods); 2) anything that lets the body decondition or overheat (long periods of inactivity, extreme heat without cooling strategies); and 3) anything that interferes with treatment safety (skipping or delaying prescribed medicines, starting high-dose supplements or live vaccines, or stopping disease-modifying therapy without your neurologist’s okay). Steering clear of these pitfalls, while staying active, eating mostly whole foods, and working closely with your MS team, gives the best chance of slowing attacks and disability.

      What is the new test for MS?

      Doctors now have a spinal-fluid test called the “kappa free light-chain (KFLC) index,” which measures tiny antibody pieces instead of looking for oligoclonal bands. In several large studies it identified multiple sclerosis with about 90–95 % sensitivity and 85–90 % specificity, is run on an automated machine (so it’s faster, cheaper, and less subjective), and many centers are beginning to add it to the standard work-up, although it still requires a lumbar puncture and currently complements rather than fully replaces oligoclonal-band testing.

      Is MS a disability?

      Multiple sclerosis is recognized by disability laws in the U.S., U.K., Canada and many other countries, but you are considered “disabled” only if your specific symptoms—such as fatigue, vision loss, or mobility problems—limit everyday tasks or steady work despite treatment. Because MS progression varies widely (some stay mild for decades while roughly one-third need a cane within 15 years), keep detailed medical records and talk with your neurologist, employer, or a benefits adviser early to document limitations, request job accommodations, or file for disability support if needed.

      How many brain lesions are normal with MS?

      There isn’t a “normal” or required lesion count for multiple sclerosis: some people have none on the first MRI, others show a handful, and studies put the typical range at roughly 5–15 lesions. What matters more to doctors is where the spots are and whether new ones appear over time—four or more lesions, especially in key areas like around the ventricles, can raise concern for future disability, but prognosis depends on the pattern and evolution rather than any single number.

      Has anyone reversed MS?

      So far no treatment has reliably “turned MS off” for everyone, but limited reversal of disability can occur. Many patients regain some or all lost function after a relapse, and small clinical trials of autologous stem-cell transplantation show that about 50-70 % of carefully selected, highly active cases improve their disability scores for several years, though the procedure carries notable risks and is not yet routine care. Current disease-modifying drugs aim to prevent new damage, and research into remyelination medicines is underway, but a guaranteed, widely available way to reverse MS does not yet exist.

      Are MS cases on the rise?

      Yes, the head-count of people living with multiple sclerosis is climbing worldwide—up roughly one-third since 1990—largely because people are being diagnosed earlier and living longer with the disease. New cases per year (incidence) have risen only modestly and unevenly, suggesting that improved detection and better treatments, rather than an explosive growth in risk, account for most of the increase, though lifestyle factors such as low vitamin D, obesity, smoking and EBV infection may also play a smaller role.

      Does MS run in families?

      MS can cluster in families, but it is not passed down in a simple all-or-nothing way: the lifetime chance is about 1 in 300 for anyone, rises to roughly 1 in 30 (≈2–3 %) if you have a parent, child, or sibling with MS, and even identical twins match only about 1 in 4 times—proof that genes are only part of the story. Because most relatives never develop the disease, routine genetic testing isn’t recommended; instead, general health steps that may lower risk (adequate vitamin D, avoiding smoking, healthy weight) are sensible for everyone.

      What is the progressive treatment for MS?

      Treatment for progressive MS has two parts. First, disease-modifying drugs such as ocrelizumab (for primary-progressive) and siponimod or, in some cases, cladribine/rituximab (for active secondary-progressive) can slow further disability when started early under an MS specialist’s care. Second, an ongoing personalised plan—physiotherapy and exercise, medicines for spasticity, pain, bladder or fatigue, plus good sleep, diet, vaccination and prompt treatment of infections—helps control day-to-day symptoms and prevents complications, with regular reviews to adjust both pieces as the condition evolves.